恩替卡韦抗肝纤维化临床观察

The clinical features of hepatitis B liver fibrosis and Treatment

目的:观察乙型肝炎肝纤维化的生化学特点与恩替卡韦治疗疗效。方法:将64例慢性乙型肝炎患者随机平分为2组:对照组给予普通护肝药物治疗,疗程6个月。治疗组还予恩替卡韦0.5mg/d口服,疗程6个月。结果:恩替卡韦组肝纤维化指标改善情况和临床疗效与对照组比较差异有统计学意义(P均<0.05);两组都无明显不良反应。结论:恩替卡韦改善慢性乙型病毒性肝炎肝纤维化疗效明确,无明显不良反应,值得临床推广应用。

Objective To observe the clinical features of hepatitis B liver fibrosis with entecavir therapy.Methods 64 patients with chronic hepatitis B patients were randomly divided into two groups：control group was given normal Liver drug therapy,The treatment group was also to entecavir 0.5 mg/d orally,the treatment was 6 months.Results entecavir group of indicators to improve the situation of liver fibrosis and the clinical efficacy compared with the control group there was a significant difference（P〈0.05）;the two groups had no obvious adverse reactions.Conclusions Entecavir treatment of chronic hepatitis B liver fibrosis effect of clear,no obvious adverse reactions,should be popularized.